San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Aristea Therapeutics is raising $62,620,986.00 in new funding. Sources indicate as part of senior management President, James Mackay played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aristea Therapeutics

Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea’s lead program, RIST4721, is currently in Phase 2 clinical development. Aristea is headquartered in San Diego, CA.

To learn more about Aristea Therapeutics, visit http://aristeatx.com/

Contact:
James Mackay, President
858-987-4064
https://www.linkedin.com/in/james-m-mackay/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved